Abstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and continues to present significant challenges in early diagnosis, precise subtyping, and prognosis assessment. In recent years, the field of biomarker research has undergone a profound paradigm shift from static concentration measurements to functional activity detection. The most revolutionary breakthrough is the α-synuclein seed amplification assay (α-Syn-SAA), which enables ultrasensitive and specific detection of pathological α-Syn in both clinical and prodromal stages, thus providing an unprecedented window for early intervention. Substantial progress has also been made in the development of biomarkers such as neurofilament light chain (NfL), Alzheimer’s disease-related biomarkers, and genetic biomarkers, as well as in detection technologies based on peripheral samples. The integrated application of cutting-edge technologies, such as real-time quaking-induced conversion (RT-QuIC), high-resolution mass spectrometry, and high-field magnetic resonance imaging (MRI), is advancing the field into a new stage characterized by a focus on pathological activity, multi-omics integration, and non- or minimally invasive approaches. In this review, we explore recent advances in PD biomarkers, focusing on core pathophysiological markers. We examine the potential of multi-omics and artificial intelligence (AI) to enhance diagnostic, subtyping, and prognostic accuracy, while also outlining the pivotal role and future directions of biomarkers in advancing precision medicine for PD.

帕金森病生物标志物研究进展：从分子病理到精准诊断

[1]AamodtWW, WaligorskaT, ShenJC, et al., 2021. Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov Disord, 36(12):2945-2950.

[2]Agin-LiebesJ, LodgeA, ReddyH, et al., 2025. α-Synuclein biomarker assays: bridging research and patient care. Lancet Neurol, 24(8):681-697.

[3]AppletonE, KhosousiS, TaM, et al., 2024. DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease. Transl Neurodegener, 13:31.

[4]AtikA, StewartT, ZhangJ, 2016. Alpha-synuclein as a biomarker for Parkinson’s disease. Brain Pathol, 26(3):410-418.

[5]BäckströmD, LinderJ, Jakobson MoS, et al., 2020. NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology, 95(7):e827-e838.

[6]BadoudS, NicastroN, GaribottoV, et al., 2016. Distinct spatiotemporal patterns for disease duration and stage in Parkinson’s disease. Eur J Nucl Med Mol Imaging, 43(3):509-516.

[7]BarbourR, KlingK, AndersonJP, et al., 2008. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis, 5(2):55-59.

[8]BartlM, XylakiM, BährM, et al., 2022. Evidence for immune system alterations in peripheral biological fluids in Parkinson’s disease. Neurobiol Dis, 170:105744.

[9]BellomoG, de LucaCMG, PaolettiFP, et al., 2022. α-Synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology, 99(5):195-205.

[10]BergD, BorghammerP, FereshtehnejadSM, et al., 2021. Prodromal Parkinson disease subtypes – key to understanding heterogeneity. Nat Rev Neurol, 17(6):349-361.

[11]BlauwendraatC, NallsMA, SingletonAB, 2020. The genetic architecture of Parkinson’s disease. Lancet Neurol, 19(2):170-178.

[12]BorscheM, KönigIR, DelcambreS, et al., 2020. Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism. Brain, 143(10):3041-3051.

[13]BraakH, del TrediciK, RübU, et al., 2003. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging, 24(2):197-211.

[14]BregendahlM, KayaZB, SingerW, et al., 2025. Alpha-synuclein seeding amplification assays in Lewy body dementia: a brief review. Mol Neurodegener, 20:77.

[15]BrzenczekC, KlopfensteinQ, HähnelT, et al., 2024. Integrating digital gait data with metabolomics and clinical data to predict outcomes in Parkinson’s disease. NPJ Digit Med, 7:235.

[16]BsoulR, McWilliamOH, WaldemarG, et al., 2025. Accurate detection of pathologic α-synuclein in CSF, skin, olfactory mucosa, and urine with a uniform seeding amplification assay. Acta Neuropathol Commun, 13:113.

[17]Concha-MarambioL, WeberS, FarrisCM, et al., 2023a. Accurate detection of α-synuclein seeds in cerebrospinal fluid from isolated rapid eye movement sleep behavior disorder and patients with Parkinson’s disease in the denovo Parkinson (DeNoPa) cohort. Mov Disord, 38(4):567-578.

[18]Concha-MarambioL, PritzkowS, ShahnawazM, et al., 2023b. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat Protoc, 18(4):1179-1196.

[19]CortésA, PhungTK, de MenaL, et al., 2025. In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s disease. Brain, 148(6):2075-2092.

[20]CoughlinDG, ShifflettB, FarrisCM, et al., 2025. α-Synuclein seed amplification assay amplification parameters and the risk of progression in prodromal Parkinson disease. Neurology, 104(5):e210279.

[21]CuiSS, DuJJ, LiuSH, et al., 2019. Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson’s disease: a pilot multicenter study. Mov Disord, 34(1):138-141.

[22]deBartolo MI, BelvisiD, MancinelliR, et al., 2024. A systematic review of salivary biomarkers in Parkinson’s disease. Neural Regen Res, 19(12):2613-2625.

[23]de LopeEG, LooRTJ, RauschenbergerA, et al., 2024. Comprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism. NPJ Parkinson’s Dis, 10:68.

[24]den HeijerJM, CullenVC, PereiraDR, et al., 2023. A biomarker study in patients with GBA1-Parkinson’s disease and healthy controls. Mov Disord, 38(5):783-795.

[25]DennisAGP, StrafellaAP, 2024. The role of AI and machine learning in the diagnosis of Parkinson’s disease and atypical parkinsonisms. Parkinsonism Relat Disord, 126:106986.

[26]EidelbergD, MoellerJR, DhawanV, et al., 1994. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab, 14(5):783-801.

[27]EllerM, WilliamsDR, 2009. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol, 5(10):561-570.

[28]EusebiP, GiannandreaD, BiscettiL, et al., 2017. Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord, 32(10):1389-1400.

[29]GalperJ, DeanNJ, PickfordR, et al., 2022. Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease. Brain, 145(10):3472-3487.

[30]GaoL, TangHM, NieK, et al., 2015. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis. Int J Neurosci, 125(9):645-654.

[31]GibbonsCH, LevineT, AdlerC, et al., 2024. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA, 331(15):1298-1306.

[32]GiladiN, AlcalayRN, CutterG, et al., 2023. Safety and efficacy of venglustat in GBA1-associated Parkinson’s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol, 22(8):661-671.

[33]GilboaT, Ter-OvanesyanD, WangSC, et al., 2024. Measurement of α-synuclein as protein cargo in plasma extracellular vesicles. Proc Natl Acad Sci USA, 121(45):e2408949121.

[34]González-FernándezMC, LezcanoE, RossOA, et al., 2007. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat Disord, 13(8):509-515.

[35]Gonzalez-LatapiP, BustosB, DongSY, et al., 2024. Alterations in blood methylome as potential epigenetic biomarker in sporadic Parkinson’s disease. Ann Neurol, 95(6):1162-1172.

[36]GrilloP, Concha-MarambioL, PisaniA, et al., 2025. Association between the amplification parameters of the α- synuclein seed amplification assay and clinical and genetic subtypes of Parkinson’s disease. Mov Disord, 40(2):305-314.

[37]GuoM, WangJ, ZhaoYX, et al., 2020. Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease. Brain, 143(5):1476-1497.

[38]HallerS, HeNY, SchwarzS, et al., 2025. Clinical MRI biomarkers to differentiate Parkinson disease from its mimics. Radiology, 317(1):e242044.

[39]HanssonO, JanelidzeS, HallS, et al., 2017. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology, 88(10):930-937.

[40]HeNY, GhassabanK, HuangP, et al., 2021. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson’s disease. Neuroimage, 230:117810.

[41]HongCT, ChungCC, HsiehYC, et al., 2025. Plasma extracellular vesicle pathognomonic proteins as the biomarkers of the progression of Parkinson’s disease. Biosci Trends, 19(1):116-124.

[42]HuangXD, FangY, SongJ, et al., 2025. Rescuing lysosomal/autophagic defects via nanoapproach: implications for lysosomal/autophagic defect-related diseases. J Zhejiang Univ-Sci B, 26(9):813-842.

[43]IranzoA, ValldeoriolaF, LomeñaF, et al., 2011. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol, 10(9):797-805.

[44]IranzoA, MammanaA, Muñoz-LopetegiA, et al., 2023. Misfolded α-synuclein assessment in the skin and CSF by RT-QuIC in isolated REM sleep behavior disorder. Neurology, 100(18):e1944-e1954.

[45]IrwinDJ, FedlerJ, CoffeyCS, et al., 2020. Evolution of Alzheimer’s disease cerebrospinal fluid biomarkers in early Parkinson’s disease. Ann Neurol, 88(3):574-587.

[46]JellingerKA, 2019. Is Braak staging valid for all types of Parkinson’s disease? J Neural Transm, 126(4):423-431.

[47]JiangC, HopfnerF, KatsikoudiA, et al., 2020. Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry, 91(7):720-729.

[48]KaliaLV, LangAE, 2015. Parkinson’s disease. Lancet, 386(9996):896-912.

[49]KarayelO, Virreira WinterS, PadmanabhanS, et al., 2022. Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson’s disease. Cell Rep Med, 3(6):100661.

[50]KayedR, DettmerU, LesnéSE, 2020. Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: expression, spreading, and cross-talk. J Parkinsons Dis, 10(3):791-818.

[51]KlugeA, SchaefferE, BunkJ, et al., 2024. Detecting misfolded α-synuclein in blood years before the diagnosis of Parkinson’s disease. Mov Disord, 39(8):1289-1299.

[52]Konstantin NissenS, FarmenK, CarstensenM, et al., 2022. Changes in CD163, CD11b, and CCR2 peripheral monocytes relate to Parkinson’s disease and cognition. Brain Behav Immun, 101:182-193.

[53]KuzkinaA, BargarC, SchmittD, et al., 2021. Diagnostic value of skin RT-QuIC in Parkinson’s disease: a two-laboratory study. npj Parkinsons Dis, 7:99.

[54]LawtonM, BaigF, ToulsonG, et al., 2020. Blood biomarkers with Parkinson’s disease clusters and prognosis: the oxford discovery cohort. Mov Disord, 35(2):279-287.

[55]LesageS, DürrA, TazirM, et al., 2006. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med, 354(4):422-423.

[56]LinCH, LiCH, YangKC, et al., 2019. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology, 93(11):e1104-e1111.

[57]LiuN, ZhangTJ, ZhaoW, et al., 2025. Current trends in blood biomarkers detection and neuroimaging for Parkinson’s disease. Ageing Res Rev, 104:102658.

[58]LukKC, KehmV, CarrollJ, et al., 2012. Pathological α- synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 338(6109):949-953.

[59]MahlknechtP, KrismerF, PoeweW, et al., 2017. Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson’s disease. Mov Disord, 32(4):619-623.

[60]MajbourNK, VaikathNN, van DijkKD, et al., 2016. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease. Mol Neurodegener, 11:7.

[61]MarquesTM, van RumundA, OecklP, et al., 2019. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology, 92(13):e1479-e1486.

[62]MiglisMG, AdlerCH, AntelmiE, et al., 2021. Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol, 20(8):671-684.

[63]MitchellT, LehéricyS, ChiuSY, et al., 2021. Emerging neuroimaging biomarkers across disease stage in Parkinson disease: a review. JAMA Neurol, 78(10):1262-1272.

[64]MollenhauerB, DaknaM, KruseN, et al., 2020. Validation of serum neurofilament light chain as a biomarker of Parkinson’s disease progression. Mov Disord, 35(11):1999-2008.

[65]MontineTJ, ShiM, QuinnJF, et al., 2010. CSF Aβ₄₂ and tau in Parkinson’s disease with cognitive impairment. Mov Disord, 25(15):2682-2685.

[66]Muñoz-LopetegiA, BaiardiS, BalasaM, et al., 2024. CSF markers of neurodegeneration Alzheimer’s and Lewy body pathology in isolated REM sleep behavior disorder. npj Parkinsons Dis, 10:157.

[67]MüllerL, ÖzdüzencilerP, Schedlich-TeuferC, et al., 2025. Elevated α-synuclein aggregate levels in the urine of patients with isolated REM sleep behavior disorder and Parkinson’s disease. Ann Neurol, 98(1):147-151.

[68]O'KeeffeGW, SullivanAM, 2018. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson’s disease. Parkinsonism Relat Disord, 56:9-15.

[69]OkuzumiA, HatanoT, MatsumotoG, et al., 2023. Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med, 29(6):1448-1455.

[70]OosterveldLP, VerberkIMW, MajbourNK, et al., 2020. CSF or serum neurofilament light added to α-synuclein panel discriminates Parkinson’s from controls. Mov Disord, 35(2):288-295.

[71]OzeliusLJ, SenthilG, Saunders-PullmanR, et al., 2006. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med, 354(4):424-425.

[72]ParnettiL, GaetaniL, EusebiP, et al., 2019. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol, 18(6):573-586.

[73]PaslawskiW, KhosousiS, HertzE, et al., 2023. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease. Transl Neurodegener, 12:42.

[74]PengC, GathaganRJ, CovellDJ, et al., 2018. Cellular milieu imparts distinct pathological α-synuclein strains in α- synucleinopathies. Nature, 557(7706):558-563.

[75]PihlstrømL, BergeV, RengmarkA, et al., 2015. Parkinson’s disease correlates with promoter methylation in the α- synuclein gene. Mov Disord, 30(4):577-580.

[76]PoeweW, 2019. Smelling Parkinson’s disease: new metabolomic biomarker for PD. ACS Cent Sci, 5(4):575-576.

[77]PolymeropoulosMH, LavedanC, LeroyE, et al., 1997. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science, 276(5321):2045-2047.

[78]PostumaRB, AdlerCH, DuggerBN, et al., 2015. REM sleep behavior disorder and neuropathology in Parkinson’s disease. Mov Disord, 30(10):1413-1417.

[79]PostumaRB, IranzoA, HuM, et al., 2019. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 142(3):744-759.

[80]RealR, Martinez-CarrascoA, ReynoldsRH, et al., 2023. Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia. Brain, 146(5):1873-1887.

[81]RussoMJ, OrruCD, Concha-MarambioL, et al., 2021. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease. Acta Neuropathol Commun, 9:179.

[82]RutledgeJ, LehallierB, ZarifkarP, et al., 2024. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease. Acta Neuropathol, 147:52.

[83]SchalkampAK, PeallKJ, HarrisonNA, et al., 2023. Wearable movement-tracking data identify Parkinson’s disease years before clinical diagnosis. Nat Med, 29(8):2048-2056.

[84]SchindlbeckKA, EidelbergD, 2018. Network imaging biomarkers: insights and clinical applications in Parkinson’s disease. Lancet Neurol, 17(7):629-640.

[85]SchwarzST, AfzalM, MorganPS, et al., 2014. The ‘swallow tail’ appearance of the healthy nigrosome – a new accurate test of Parkinson’s disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One, 9(4):e93814.

[86]ShahmoradianSH, LewisAJ, GenoudC, et al., 2019. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat Neurosci, 22(7):1099-1109.

[87]ShahnawazM, TokudaT, WaragaiM, et al., 2017. Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol, 74(2):163-172.

[88]ShahnawazM, MukherjeeA, PritzkowS, et al., 2020. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature, 578(7794):273-277.

[89]ShaoYP, LeWD, 2019. Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease. Mol Neurodegener, 14:3.

[90]ShaoYP, LiTB, LiuZY, et al., 2021. Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry. Mol Neurodegener, 16:4.

[91]SiderowfA, Concha-MarambioL, LafontantDE, et al., 2023. Assessment of heterogeneity among participants in the Parkinson’s progression markers initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol, 22(5):407-417.

[92]SimuniT, ChahineLM, PostonK, et al., 2024. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol, 23(2):178-190.

[93]SingerW, SchmeichelAM, ShahnawazM, et al., 2020. Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies. Ann Neurol, 88(3):503-512.

[94]SongW, KothariV, VellyAM, et al., 2018. Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson’s disease. Mov Disord, 33(4):583-591.

[95]SuDN, CuiYS, HeCZ, et al., 2025. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021. BMJ, 388:e080952.

[96]SungYH, NohY, LeeJ, et al., 2016. Drug-induced parkinsonism versus idiopathic Parkinson disease: utility of nigrosome 1 with 3-T imaging. Radiology, 279(3):849-858.

[97]TangCC, PostonKL, EckertT, et al., 2010. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol, 9(2):149-158.

[98]TolosaE, GarridoA, ScholzSW, et al., 2021. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol, 20(5):385-397.

[99]TsukitaK, Sakamaki-TsukitaH, TanakaK, et al., 2019. Value of in vivo α-synuclein deposits in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord, 34(10):1452-1463.

[100]WangCL, ChenL, YangY, et al., 2019. Identification of potential blood biomarkers for Parkinson’s disease by gene expression and DNA methylation data integration analysis. Clin Epigenetics, 11:24.

[101]WangJ, XueL, JiangJH, et al., 2024. Diagnostic performance of artificial intelligence-assisted PET imaging for Parkinson’s disease: a systematic review and meta-analysis. npj Digit Med, 7:17.

[102]WangJY, SongYD, ZhangDL, et al., 2025. Detection of early Parkinson’s disease using 5-hydroxymethylcytosine episignatures in blood DNA. Age Ageing, 54(6):afaf147.

[103]WangZR, BeckerK, DonadioV, et al., 2021. Skin α-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol, 78(1):30-40.

[104]WangZR, GillilandT, KimHJ, et al., 2024. A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson’s disease. Acta Neuropathol Commun, 12:167.

[105]WilsonEN, SwarovskiMS, LinortnerP, et al., 2020. Soluble TREM2 is elevated in Parkinson’s disease subgroups with increased CSF tau. Brain, 143(3):932-943.

[106]XuW, ChenLN, CaiGE, et al., 2023. Diagnosis of Parkinson’s disease via the metabolic fingerprint in saliva by deep learning. Small Methods, 7(7):2300285.

[107]XylakiM, ChopraA, WeberS, et al., 2023. Extracellular vesicles for the diagnosis of Parkinson’s disease: systematic review and meta-analysis. Mov Disord, 38(9):1585-1597.

[108]YanSJ, JiangC, JanzenA, et al., 2024. Neuronally derived extracellular vesicle α-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease. JAMA Neurol, 81(1):59-68.

[109]YanSJ, ZhangWJ, LiXY, et al., 2025. Single extracellular vesicle detection assay identifies membrane-associated α-synuclein as an early-stage biomarker in Parkinson’s disease. Cell Rep Med, 6(3):101999.

[110]YangBY, ZhuYY, LiKL, et al., 2024. Machine learning model base on metabolomics and proteomics to predict cognitive impairment in Parkinson’s disease. npj Parkinsons Dis, 10:187.

[111]YangZF, WangY, WeiM, et al., 2023. Intrastriatal injection of Parkinson’s disease intestine and vagus lysates initiates α-synucleinopathy in rat brain. Cell Death Dis, 14:4.

[112]YeH, RobakLA, YuMG, et al., 2023. Genetics and pathogenesis of Parkinson’s syndrome. Annu Rev Pathol Mech Dis, 18:95-121.

[113]YuZW, ZhengYC, CaiHH, et al., 2024. Molecular beacon-based detection of circulating microRNA-containing extracellular vesicle as an α-synucleinopathy biomarker. Sci Adv, 10(20):eadl6442.

[114]YuZY, SaikiS, ShiinaK, et al., 2024. Comprehensive data for studying serum exosome microRNA transcriptome in Parkinson’s disease patients. Sci Data, 11:1128.

[115]ZhangJD, XueCH, KolachalamaVB, et al., 2023. Interpretable machine learning on metabolomics data reveals biomarkers for Parkinson’s disease. ACS Cent Sci, 9(5):1035-1045.

[116]ZhaoY, WuP, WuJJ, et al., 2022. Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning. Eur J Nucl Med Mol Imaging, 49(8):2798-2811.

[117]ZhengYC, YuZW, CaiHH, et al., 2024. Detection of α- synuclein in oral mucosa by seed amplification assay in synucleinopathies and isolated REM sleep behavior disorder. Mov Disord, 39(8):1300-1309.

[118]ZhouB, WenM, YuWF, et al., 2015. The diagnostic and differential diagnosis utility of cerebrospinal fluid α-synuclein levels in Parkinson’s disease: a meta-analysis. Parkinsons Dis, 2015:567386.

Similar articles